Stress-associated weight gain, fibromyalgia symptoms, cardiometabolic markers, and human growth hormone suppression respond to an amino acid supplement blend: Results of a prospective, cohort study.

What Was Tested

This observational study looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and Copper (Supplement).

Who Took Part

According to the abstract, 84 patients were involved.

PubMed indexes the participants as adults.

Participants continued to receive standard care.

The study enrolled 84 fibromyalgia patients with low-normal age-adjusted IGF-1 serum levels.

How the Study Was Run

The primary endpoint was the change from baseline to endpoint (Week 24) in serum IGF-1.

Additional endpoints included the change in body weight, clinical symptoms (assessed with the Revised Fibromyalgia Impact Questionnaire [FIQR], range 0-100, and Perceived Stress Scale [PSS], range 0-40), fasting cardiometabolic markers, tolerability, and safety.

High mean ± Standard Deviation (SD) baseline FIQR and PSS scores of 76 ± 16 and 32 ± 5, respectively, indicated poor to moderate symptom management with standard care.

All individuals completed 24 weeks.

What Was Measured

The subject headings attached to it are Human Growth Hormone, Fibromyalgia, Insulin-Like Growth Factor I, Cohort Studies, Weight Gain, Surveys and Questionnaires and Amino Acids.

Author keywords: somatostatin and stress-related weight gain.

What This Means in Plain Language

This is an observational study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and Copper (Supplement) in 84 patients.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2023 (Frontiers in endocrinology), a journal based in Switzerland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the Copper (Supplement) compound page, all human trials.